<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Central neuropathic facial pain</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Central neuropathic facial pain</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Central neuropathic facial pain</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ivan Garza, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Elizabeth Robertson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Central facial pain is a syndrome characterized by intermittent or continuous neuropathic pain caused by a lesion or dysfunction in the central nervous system. Pain may be accompanied by sensory loss and can develop weeks to months or even years after the onset of the central lesion.</p><p>The International Classification of Headache Disorders (ICHD) recognizes two entities that are central causes of facial pain [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Central neuropathic pain attributed to multiple sclerosis</p><p class="bulletIndent1"><span class="glyph">●</span>Central poststroke pain</p><p></p><p>This topic will discuss the clinical features, diagnosis, and management of central neuropathic facial pain. Other causes of neuropathic facial pain, including persistent idiopathic (atypical) facial pain, cranial neuralgias, and painful cranial neuropathies, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3355.html" rel="external">"Overview of craniofacial pain"</a>.)</p><p>Other manifestations of pain associated with multiple sclerosis and stroke are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">"Symptom management of multiple sclerosis in adults", section on 'Pain'</a> and  <a class="medical medical_review" href="/z/d/html/131658.html" rel="external">"Neuropalliative care of stroke", section on 'Pain'</a>.)</p><p class="headingAnchor" id="H3792766832"><span class="h1">PATHOPHYSIOLOGY</span></p><p class="headingAnchor" id="H2"><span class="h2">Anatomy</span><span class="headingEndMark"> — </span>Central neuropathic pain is due to dysfunction in the central nervous system. Neuropathic facial pain may be caused by a lesion at any level of the central nervous system involved in facial sensation, from the spinal trigeminal nucleus or spinal dorsal horn rostral up to the cerebral cortex. Common sites include the lateral aspect of the medulla, pontine base, and lateral or posterior thalamus [<a href="#rid2">2,3</a>]. The risk for developing central pain may be higher when the spinothalamic and quintothalamic pathways are affected compared to suprathalamic lesions involving other pathways [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The underlying pathogenesis of central neuropathic facial pain is uncertain. The pathophysiology may be similar to neuropathic pain elsewhere in the body or due to other types of lesions, due to overlapping features and associated conditions [<a href="#rid5">5</a>]. Several peripheral and central mechanisms have been implicated in neuropathic pain pathophysiology (brain, spinal cord, and descending modulating systems) [<a href="#rid6">6</a>]. However, the certainty in the underlying mechanisms of central neuropathic facial pain is limited by observed variability in clinical features and localization within the central nervous system.</p><p>Although the mechanisms of central neuropathic facial pain remain poorly understood [<a href="#rid7">7</a>], two general mechanisms have been implicated:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irritative lesion hypothesis</strong> – An "irritative lesion" has been posited to lead to excess activity in otherwise normal somatosensory pathways. Lesion-induced hyperactivity may impair physiologic balance of facilitation and inhibition [<a href="#rid8">8,9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postdenervation sensitization hypothesis</strong> – Neurons remote from the lesion site may become hyperactive and hypersensitive after losing regulatory synaptic inputs through denervation [<a href="#rid4">4</a>]. This release from inhibition may result in an abnormal, sensitized state of central structures leading to persistent pain in the absence of ongoing tissue injury [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H1587812312"><span class="h1">CAUSE-SPECIFIC EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The overall prevalence of central neuropathic facial pain is uncertain, as rates vary by underlying cause and because available epidemiologic data are limited.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central neuropathic pain from multiple sclerosis</strong> – In a meta-analysis of 24 observational studies of neuropathic pain among patients with multiple sclerosis, the overall prevalence of neuropathic pain was approximately 27 percent [<a href="#rid11">11</a>]. However, the proportion of patients with neuropathic facial pain in these patients was not specified. General facial pain has been reported to occur in up to 5 percent of patients with multiple sclerosis, but many of these cases appear to be due to trigeminal (peripheral) neuralgia [<a href="#rid12">12</a>]. In one study of 377 patients with early multiple sclerosis (mean disease duration 4.2 years), the prevalence of neuropathic pain was 4.2 percent [<a href="#rid13">13</a>]. Of these 16 patients, only one patient had isolated facial pain (trigeminal neuralgia), five had facial pain combined with pain in extremities, and the rest had other locations of neuropathic pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poststroke pain</strong> – Central facial pain affects from 0.5 up to 8 percent of patients following stroke [<a href="#rid14">14-17</a>]. Among patients with stroke producing sensory deficits, the prevalence of central poststroke pain may be as high as 18 percent [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H2703425521"><span class="h2">Facial pain</span><span class="headingEndMark"> — </span>Clinically, the presentation of central neuropathic facial pain can vary significantly in severity, character, and location.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity</strong> – Pain intensity can range from mild to excruciating [<a href="#rid4">4</a>]. The pain can be a great burden in some patients due to severity and refractoriness, leading to severe depression or even suicide [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Character of pain</strong> – The character of central neuropathic facial pain is variable [<a href="#rid19">19,20</a>]. Patients may report muscle pain, felt as cramping, constriction, or crushing. Others may feel a burning- or freezing-type dysesthesia or circulatory-like pain (pins and needles, stings, jabs).</p><p></p><p class="bulletIndent1">Nevertheless, central pain can often be difficult for patients to describe, and many patients report more than one type of pain [<a href="#rid4">4</a>]. Bizarre, vague terms such as troublesome, annoying, or tiring might be utilized by patients attempting to explain what they are feeling [<a href="#rid19">19,21</a>].</p><p></p><p class="bulletIndent1">Internal and external stimuli can exacerbate or trigger central pain. Common triggers include cold, movement, light touch, or emotional distress [<a href="#rid4">4</a>]. These triggers may produce allodynia (interpretation of nonpainful stimuli as painful) and/or hyperalgesia (a heightened response to noxious stimuli).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Temporal features</strong> – Neuropathic facial pain can be constant or intermittent and may occur spontaneously or in response to a stimulus. Most patients report constant (non-neuralgic) pain that is associated with spontaneous or triggered exacerbations. Other patients have intermittent (neuralgic) pain that is paroxysmal, episodic, and shooting/lancinating in quality (similar to the pain with trigeminal neuralgia) [<a href="#rid7">7,22</a>]. Neuropathic facial pain that is exclusively neuralgic is uncommon but has been reported in some patients with pontine ischemic infarction [<a href="#rid23">23,24</a>].</p><p></p><p class="bulletIndent1">Central neuropathic facial pain is typically a persistent, chronic condition. (See <a class="local">'Prognosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Location</strong> – Central neuropathic facial pain can occur in a discrete area or the entire side of the face/head. Pain can also more broadly involve the entire craniocervical region [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1">Additional sites of neuropathic pain symptoms may be present elsewhere in the body depending on the localization of the underlying central lesion [<a href="#rid25">25,26</a>].</p><p></p><p class="headingAnchor" id="H522211719"><span class="h2">Attributable central lesion</span></p><p class="headingAnchor" id="H3922111445"><span class="h3">Sensory symptoms</span><span class="headingEndMark"> — </span>Central neuropathic facial pain results from ischemic or demyelinating central nervous system lesions that produce initial or persistent sensory loss. Patients frequently have hypoesthesia, anesthesia, and/or hypoalgesia associated with the pain. Abnormalities in temperature sensation may be reported by patients [<a href="#rid27">27</a>]. However, central pain can also occur after minor or clinically silent brain lesions, including those that leave no permanent, clinically detectable sensory loss [<a href="#rid7">7</a>]. In some patients, the causal central lesion may be identified by imaging performed following the onset of facial pain symptoms.</p><p class="headingAnchor" id="H251322148"><span class="h3">Relation to onset of pain</span><span class="headingEndMark"> — </span>Onset of central neuropathic facial pain typically occurs weeks to months following the onset of transiently lost or impaired sensation from a lesion affecting somatosensory pathways [<a href="#rid27">27</a>]. However, in some patients, the onset of facial pain may coincide with the acute central lesion. In others, the onset of the pain may be delayed for years after the insult [<a href="#rid4">4,16,27</a>]. In a systematic review of 16 studies that reported the incidence of central poststroke pain, symptoms occurred with stroke onset in 26 percent of patients, within one month in 31 percent, between one month and one year in 41 percent, and more than 12 months after the stroke in 5 percent of patients [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H2672901531"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of central neuropathic facial pain should be considered in patients with unilateral or bilateral facial pain that occurs following onset of a demyelinating or ischemic lesion of the central nervous system. The diagnosis is made in patients who fulfill diagnostic criteria for either central neuropathic pain attributed to multiple sclerosis or central poststroke pain. Diagnostic testing, including neuroimaging, is required to identify a causal lesion and exclude alternative causes of pain.</p><p>The diagnosis of central neuropathic pain conditions from demyelinating or ischemic lesions that do not involve the head/face is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">"Symptom management of multiple sclerosis in adults", section on 'Pain'</a> and  <a class="medical medical_review" href="/z/d/html/131658.html" rel="external">"Neuropalliative care of stroke", section on 'Pain'</a>.)</p><p class="headingAnchor" id="H1624735242"><span class="h2">Diagnostic criteria</span></p><p class="headingAnchor" id="H93883932"><span class="h3">Central neuropathic pain attributed to multiple sclerosis</span><span class="headingEndMark"> — </span>Central neuropathic pain attributed to multiple sclerosis is described as unilateral or bilateral craniocervical pain of varying presentation, with or without sensory changes, attributed to a demyelinating lesion of the central connections of the trigeminal nerve in an individual with multiple sclerosis [<a href="#rid1">1</a>].</p><p>Diagnostic criteria, according to the International Classification of Headache Disorders, 3<sup>rd</sup> edition (ICHD-3), require all of the following [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Facial and/or head pain</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple sclerosis has been diagnosed with magnetic resonance imaging (MRI) demonstration of a demyelinating lesion in the brain stem or ascending projections of the trigeminal nuclei</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain has developed in temporal relation to the demyelinating lesion or led to its discovery</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Not better accounted for by another ICHD-3 diagnosis</p><p></p><p>The pain may be continuous or paroxysmal. Other associated sensory disturbances may include dysesthesia, hypoesthesia, anesthesia, hypoalgesia, and paresthesia [<a href="#rid1">1</a>].</p><p>Patients with multiple sclerosis who have unilateral pain with the characteristics of (secondary) trigeminal neuralgia due to a multiple sclerosis plaque affecting the peripheral trigeminal nerve root should be classified instead as having trigeminal neuralgia attributed to multiple sclerosis [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/5283.html" rel="external">"Trigeminal neuralgia", section on 'Mechanisms'</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Central poststroke pain</span><span class="headingEndMark"> — </span>Central poststroke pain is described as usually unilateral facial and/or head pain, with variable presentation, involving part or the whole of the craniocervical region and associated with impaired sensation that is caused by stroke [<a href="#rid1">1</a>]. It is not caused by a lesion of the peripheral trigeminal nerve or other cranial or cervical nerves. Depending on the specific site of the lesion, the ipsilateral trunk and/or limbs may also be affected.</p><p>Diagnostic criteria for central poststroke pain according to the ICHD-3 require all of the following [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Facial and/or head pain</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ischemic or hemorrhagic stroke has occurred</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of causation demonstrated by both of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pain has developed within six months after the stroke</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Imaging (usually MRI) has demonstrated a vascular lesion in an appropriate site</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Not better accounted for by another ICHD-3 diagnosis</p><p></p><p>The pain is usually persistent but can also be paroxysmal [<a href="#rid18">18</a>].</p><p>In several studies and the author's experience, the onset of central poststroke pain may be delayed months or even years after the stroke, in contradistinction to the ICHD-3 diagnostic criteria [<a href="#rid4">4</a>]. (See <a class="local">'Relation to onset of pain'</a> above.)</p><p class="headingAnchor" id="H2597595061"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>The evaluation may be straightforward for patients with facial pain in the distribution of a known, recently preceding history of a demyelinating or ischemic event that produced sensory deficit. However, attributing facial pain symptoms with a central lesion may be more difficult when symptoms are atypical or a history of preceding central event is either absent or remote (eg, &gt;6 months).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Examination</strong> – For patients who present with clinical features suggestive of central neuropathic facial pain, evaluation begins with a general and neurologic examination. Direct inspection of the face, ear, mouth, and neck may identify swelling or a rash that would suggest an alternative condition. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1">Patients with central facial pain may also report allodynia or hyperalgesia on sensory testing. (See <a class="local">'Facial pain'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuroimaging</strong> – Neuroimaging is required to identify an underlying demyelinating or ischemic causal lesion for central pain symptoms, to evaluate for acute lesions that may require cause-specific treatment, and to exclude alternative conditions. Brain MRI with gadolinium contrast is the preferred imaging modality. In addition, vascular imaging with magnetic resonance (or computed tomography [CT]) angiography of the head is also performed for patients with neuralgic pain to evaluate for neurovascular compression associated with trigeminal neuralgia.</p><p></p><p class="bulletIndent1">Head CT with contrast may be performed as an alternative for patients unable to undergo a brain MRI. However, head CT is less sensitive than MRI for many central lesions that produce central neuropathic facial pain due to their small size, demyelinative etiology, and/or brain stem location.</p><p></p><p class="bulletIndent1">MRI findings in central neuropathic facial pain include acute and chronic ischemic or demyelinative lesions that involve trigeminal nuclei or ascending projections, spinothalamic pathways, and/or associated cortical regions. Lesions producing central facial pain may be found in the medulla, pons, thalamus, or cerebral hemispheres [<a href="#rid24">24-26,29</a>]. Specific imaging findings in multiple sclerosis and stroke are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults", section on 'Magnetic resonance imaging'</a> and  <a class="medical medical_review" href="/z/d/html/1085.html" rel="external">"Neuroimaging of acute stroke"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other testing</strong> – Neurophysiologic testing has limited diagnostic utility but may be performed for selected patients with nondiagnostic imaging or atypical features or features of uncertain relation to a central lesion on imaging. Somatosensory evoked potential testing may show abnormalities in patients with poststroke pain [<a href="#rid3">3,30</a>]. Trigeminal reflex testing may be used to localize facial symptoms to the peripheral trigeminal nerve.</p><p></p><p class="headingAnchor" id="H3318131911"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of central neuropathic facial pain includes other conditions that produce facial pain. These include cranial neuralgias such as trigeminal neuralgia and secondary causes of facial pain such as dental pain or giant cell arteritis. These conditions may be distinguished by specific clinical features and/or neuroimaging findings.</p><p>Specific alternative conditions vary by the site and character of pain. (See  <a class="medical medical_review" href="/z/d/html/3355.html" rel="external">"Overview of craniofacial pain"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Pharmacotherapy is the mainstay of the treatment of central neuropathic facial pain. Interventional and surgical treatments may be used for refractory cases. Therapy for central pain can be challenging. Symptoms may be severe, persistent, and often refractory to multiple treatment modalities.</p><p>Referral for specialty care should be pursued if the diagnosis is uncertain or if the patient fails to respond to usual management.</p><p>Limited scientific evidence is available regarding pharmacotherapy for central neuropathic facial pain [<a href="#rid22">22</a>]. Treatment is mostly based on evidence for other types of neuropathic pain, expert opinion, and consensus statements [<a href="#rid4">4</a>]. Various guideline groups have recommended similar although somewhat different treatment strategies for neuropathic pain [<a href="#rid31">31-34</a>]. However, it is unknown whether a treatment that is effective in one central pain syndrome will be effective in another [<a href="#rid31">31</a>]. It is therefore difficult to apply available guidelines for neuropathic or central pain management to facial pain specifically [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H3147843713"><span class="h2">Initial treatment options for most patients</span><span class="headingEndMark"> — </span>For most patients with central neuropathic facial pain, we suggest tricyclic antidepressants as initial pharmacologic therapy based on limited data for central facial pain as well as efficacy in other forms of neuropathic pain. <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">Amitriptyline</a> is the most studied tricyclic for central pain. We use gabapentinoids for patients with an intolerance, contraindication, or suboptimal response to tricyclic antidepressants.</p><p>Some patients who have neuropathic facial pain that is both neuralgic (episodic, lancinating) and non-neuralgic (constant) may benefit from combining <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> (for neuralgic pain) with <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> or <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>/<a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> (for steady, non-neuralgic pain). (See <a class="local">'Carbamazepine for patients with neuralgic pain'</a> below.)</p><p>Referral for specialty care, including evaluation for interventional options, should be pursued if the diagnosis is uncertain or if the patient fails to respond to usual management.</p><p class="headingAnchor" id="H16"><span class="h3">Tricyclic antidepressants</span><span class="headingEndMark"> — </span>For most patients with central neuropathic facial pain, we use <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> as initial pharmacologic therapy. Alternative agents in this class may be used for patients with intolerance to amitriptyline, including <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a> or <a class="drug drug_general" data-topicid="9832" href="/z/d/drug information/9832.html" rel="external">protriptyline</a>.</p><p><a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">Amitriptyline</a> is started at 10 to 25 mg nightly and titrated as needed and tolerated by 10 to 25 mg steps every one to three weeks up to a maximum dose of 150 mg nightly is reached.</p><p><a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">Amitriptyline</a> and most other tricyclics are sedating. Additional side effects of tricyclics include dry mouth, constipation, tachycardia, palpitations, orthostatic hypotension, weight gain, blurred vision, and urinary retention. Confusion can occur, particularly in older adults. These agents should be avoided or used with caution in patients with cardiovascular disease (including stroke).</p><p><a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">Amitriptyline</a> has been shown to be effective in several small randomized controlled trials of patients with central poststroke pain [<a href="#rid18">18,35,36</a>]. However, other meta-analyses and systematic reviews have not found a benefit for amitriptyline [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H3458276667"><span class="h3">Gabapentinoids</span><span class="headingEndMark"> — </span>We use gabapentinoids as initial treatment of central neuropathic facial pain for patients with an intolerance or contraindication to tricyclic antidepressants, such as those with cardiovascular disease (including stroke). Gabapentinoids are also used for patients with a suboptimal response to tricyclic antidepressants. Options in this class include <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gabapentin</strong> – <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> is started at 100 to 300 mg daily and titrated as needed and tolerated for pain relief. In patients who are poorly tolerant of side effects, the titration can be as low as 100 mg daily. Adequate relief is typically achieved with gabapentin doses ranging from 900 to 2400 mg daily, given in three divided doses [<a href="#rid38">38</a>]. Doses as high as 3600 mg daily are tolerated by most patients.</p><p></p><p class="bulletIndent1">The most common adverse effects of <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> include somnolence, diarrhea, mood swings, ataxia, fatigue, nausea, and dizziness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregabalin</strong> – <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">Pregabalin</a> is typically started at 25 to 50 mg once daily then increased as needed and tolerated by 50 to 150 mg/day (given in two to three divided doses) at weekly intervals up to a maximum total daily dose of 600 mg daily.</p><p></p><p class="bulletIndent1">Common side effects of <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> include dizziness, somnolence, dry mouth, peripheral edema, and weight gain. Pregabalin can also cause sedation and confusion. It is designated as a schedule V controlled substance in the United States because it has been reported to cause euphoria. When stopping the drug, it should be tapered over a week since withdrawal symptoms may occur.</p><p></p><p>A network meta-analysis of 13 studies that assessed medications for poststroke pain suggested that <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> and <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> were the most effective (compared with <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, and others) but also caused the most frequent adverse events [<a href="#rid36">36</a>]. Certainty of these conclusions were limited by small number and size of studies, low quality of data with risk of bias, and short-term outcome assessments. Other studies have also suggested that gabapentin and pregabalin are effective for central poststroke pain [<a href="#rid18">18,39</a>].</p><p class="headingAnchor" id="H2341263096"><span class="h2">Carbamazepine for patients with neuralgic pain</span><span class="headingEndMark"> — </span>For patients with neuralgic (brief, recurring, lancinating attacks of) facial pain attributed to multiple sclerosis or stroke, we suggest <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> as initial therapy. Evidence is from expert opinion and largely based on efficacy for neuralgic pain due to secondary trigeminal neuralgia [<a href="#rid4">4,40</a>].</p><p><a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a> is started at 100 to 200 mg daily; the dose can be increased over several weeks by 200 mg increments as needed for pain relief up to a maximum total dose of 1200 mg/day.</p><p><a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a> is associated with rare but serious side effects, including agranulocytosis and aplastic anemia. The Stevens-Johnson syndrome and toxic epidermal necrolysis are additional rare complications, particularly during the first eight weeks of therapy, and are significantly more common (estimated incidence of 5 percent) among patients with the HLA-B*1502 (human leukocyte antigen) allele [<a href="#rid41">41</a>]. This allele occurs almost exclusively in patients of South Asian ancestry. Screening for this allele is recommended in patients of these ethnic groups prior to starting carbamazepine. (See  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis", section on 'HLA polymorphism and pharmacogenetics'</a>.)</p><p>Limited evidence in patients with poststroke pain suggests a possible but uncertain benefit for <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid36">36,37</a>].</p><p class="headingAnchor" id="H399800365"><span class="h2">Alternative treatments</span><span class="headingEndMark"> — </span>We add or switch to an alternative agent for patients with an inadequate response or contraindication to initial therapy. Several other agents have been used for central neuropathic facial pain and other forms of central pain. Limited evidence from small trials and cohort studies suggests a benefit for <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a>, and <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> [<a href="#rid18">18,36,39,42-44</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lamotrigine</strong> – <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">Lamotrigine</a> is typically started at 25 mg daily for the first two weeks of therapy. The dose can then be increased as needed and tolerated to 50 mg daily for weeks 3 and 4, then by 50 mg increments every one to two weeks up to a daily maximum of 400 mg.</p><p></p><p class="bulletIndent1">Rash is the most common adverse effect associated with <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> treatment and requires discontinuation of the drug since a hypersensitivity reaction may result and lead to life-threatening complications such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Other common adverse effects include nausea and dizziness. Lamotrigine should be tapered slowly over weeks to reduce the risk of withdrawal symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duloxetine</strong> – <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">Duloxetine</a> is started at 30 mg daily and can be increased to 60 mg daily as needed and if tolerated. Common adverse reactions with duloxetine include nausea, drowsiness, and weight loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venlafaxine</strong> – <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">Venlafaxine</a> is typically started at 37.5 mg daily. The dose may be increased as needed and tolerated to 75 mg after one week then by an additional 75 mg each subsequent week up to a maximum dosage of 225 mg. Nausea and dizziness are common adverse effects with venlafaxine.</p><p></p><p>Other drugs that have been used in case series and reports of patients with neuropathic facial pain include [<a href="#rid22">22,45-47</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">Phenytoin</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">Clonazepam</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">Valproate</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">Prochlorperazine</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9648" href="/z/d/drug information/9648.html" rel="external">Mexiletine</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">Baclofen</a></p><p></p><p class="headingAnchor" id="H2309581105"><span class="h2">Avoid opioids</span><span class="headingEndMark"> — </span>We do <strong>not</strong> use opioids to treat central neuropathic facial pain. Importantly, a position statement from the American Academy of Neurology (AAN) regarding opioid use for chronic noncancer pain stated that "there is no substantial evidence for maintenance of pain relief or improved function over long periods of time without incurring serious risk of overdose, dependence, or addiction" [<a href="#rid48">48</a>]. While there is evidence for short-term pain relief using opioids (if used), these should only be part of the pain management strategy. The risks of chronic opioid therapy for chronic conditions such as headache, fibromyalgia, and chronic low back pain likely outweigh the benefits [<a href="#rid48">48</a>]. It is unclear if the same applies to chronic central neuropathic face pain, but the possibility exists, warranting judicious opioid use if at all.</p><p class="headingAnchor" id="H23"><span class="h2">Interventional treatment options for refractory cases</span><span class="headingEndMark"> — </span>Neuromodulation and invasive procedures to treat central neuropathic facial pain are reserved for patients with significant disability who have failed noninvasive measures [<a href="#rid22">22,49</a>]. Options include:</p><p class="bulletIndent1"><span class="glyph">●</span>Transcutaneous electrical nerve stimulation [<a href="#rid4">4,50</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Motor cortex stimulation [<a href="#rid51">51,52</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Spinal cord stimulation [<a href="#rid53">53-55</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Repetitive transcranial magnetic stimulation [<a href="#rid56">56,57</a>]</p><p></p><p>The evidence of efficacy for central neuropathic facial pain is limited to case reports and series as well as data for other forms of central pain. In a systematic review of case series that included 210 patients with poststroke pain who underwent motor cortex stimulation procedures, the rate of favorable response (≥40 percent pain relief) was reported in 45 percent at one year. The durable effect is uncertain; relief after motor cortex stimulation has been reported to subside with time [<a href="#rid22">22,58</a>].</p><p>Deep brain stimulation and destructive lesions, such as radiofrequency ablation or thalamotomy, are last-resort procedures only considered after other alternatives have failed and only in specialized centers [<a href="#rid4">4</a>]. Though they may provide pain relief in a subset of patients, pain may recur after these procedures as well [<a href="#rid59">59-61</a>].</p><p>Neuromodulatory and interventional options for neuropathic pain are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/126111.html" rel="external">"Approach to the management of chronic non-cancer pain in adults", section on 'Physical modalities'</a> and  <a class="medical medical_review" href="/z/d/html/126111.html" rel="external">"Approach to the management of chronic non-cancer pain in adults", section on 'Interventional therapy for chronic pain'</a>.)</p><p class="headingAnchor" id="H466933448"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Central neuropathic facial pain is a chronic, often lifelong condition that is variably responsive to treatment [<a href="#rid62">62,63</a>]. Severity of pain typically remains stable throughout the course of symptoms. Some patients are effectively managed with initial pharmacotherapy, while many others require multiple medication trials to achieve sustained pain relief. For some patients, symptoms may be partially or completely refractory to therapeutic options.</p><p class="headingAnchor" id="H4055013459"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115871.html" rel="external">"Society guideline links: Neuropathic pain"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and causes</strong> – Central facial pain is characterized by intermittent or continuous neuropathic pain caused by a lesion or dysfunction in the central nervous system. Subtypes are identified by underlying causes (see <a class="local">'Introduction'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Central neuropathic pain attributed to multiple sclerosis</p><p class="bulletIndent2"><span class="glyph">•</span>Central poststroke pain</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – A lesion at any level of the central nervous system from the spinal trigeminal nucleus or spinal dorsal horn rostral to the cerebral cortex has the potential to cause central neuropathic facial pain. (See <a class="local">'Anatomy'</a> above.)</p><p></p><p class="bulletIndent1">Mechanisms that have been hypothesized to cause central neuropathic pain include an "irritative lesion," affecting somatosensory pathways that lead to excess activity, and postdenervation sensitization, where neurons remote from the lesion site become hyperactive and hypersensitive after losing regulatory synaptic inputs. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Facial pain</strong> – Central neuropathic facial pain can cause muscle pain, felt as cramping, constriction, or crushing; burning- or freezing-type dysesthesia; or circulatory-like pain (pins and needles, stings, jabs).</p><p></p><p class="bulletIndent2">Internal and external stimuli can exacerbate or trigger central pain and include cold, movement, light touch, or emotional distress.</p><p></p><p class="bulletIndent2">Neuropathic facial pain can be constant or intermittent and may occur spontaneously or in response to a stimulus. (See <a class="local">'Facial pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Associated sensory loss</strong> – Central neuropathic facial pain results from central nervous system lesions that typically produce initial or persistent sensory loss. Patients frequently have hypoesthesia, anesthesia, and/or hypoalgesia associated with the pain. (See <a class="local">'Sensory symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Relation to causal central lesion</strong> – Onset of central neuropathic facial pain may coincide with, or shortly follow, the return of transiently lost or impaired sensation related to a lesion affecting somatosensory pathways. However, the onset of the pain may be delayed for years after the insult. (See <a class="local">'Relation to onset of pain'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of central neuropathic facial pain is made in patients who fulfill diagnostic criteria for either central neuropathic pain attributed to multiple sclerosis or central poststroke pain. Diagnostic neuroimaging is required to identify a causal lesion, to evaluate for an acute lesion that may require cause-specific treatment, and to exclude alternative conditions. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial treatment options</strong> – For most patients with central neuropathic facial pain, we suggest <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> as initial pharmacologic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We use gabapentinoids for patients with an intolerance or contraindication to tricyclic antidepressants, such as those with cardiovascular disease (including stroke). (See <a class="local">'Tricyclic antidepressants'</a> above and <a class="local">'Gabapentinoids'</a> above.)</p><p></p><p class="bulletIndent2">For patients with neuralgic (brief, lancinating attacks of) facial pain attributed to multiple sclerosis or stroke, we suggest <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> as initial therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This preference is based on efficacy for trigeminal neuralgia (eg, secondary trigeminal neuralgia). (See <a class="local">'Carbamazepine for patients with neuralgic pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternative treatment options</strong> – We add or switch to an alternative agent for patients with an inadequate response or contraindication to initial therapy. Options include <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a>, and <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>. (See <a class="local">'Alternative treatments'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory treatments</strong> – Neuromodulation and invasive procedures to treat central neuropathic facial pain are reserved for patients with significant disability who have failed noninvasive measures. (See <a class="local">'Interventional treatment options for refractory cases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Central neuropathic facial pain is a chronic, often lifelong condition that is variably responsive to treatment. Some patients respond to initial pharmacotherapy, while many others require multiple medication trials and/or long-term therapy for sustained pain relief. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.</a></li><li><a class="nounderline abstract_t">Sprenger T, Seifert CL, Valet M, et al. Assessing the risk of central post-stroke pain of thalamic origin by lesion mapping. Brain 2012; 135:2536.</a></li><li><a class="nounderline abstract_t">Misra UK, Kalita J, Kumar B. A study of clinical, magnetic resonance imaging, and somatosensory-evoked potential in central post-stroke pain. J Pain 2008; 9:1116.</a></li><li class="breakAll">Boivie J, Casey KL. Central pain in the face and head. In: The Headaches, Olesen, J (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.1063.</li><li><a class="nounderline abstract_t">Klit H, Finnerup NB, Jensen TS. Central post-stroke pain: clinical characteristics, pathophysiology, and management. Lancet Neurol 2009; 8:857.</a></li><li><a class="nounderline abstract_t">Cohen SP, Mao J. Neuropathic pain: mechanisms and their clinical implications. BMJ 2014; 348:f7656.</a></li><li class="breakAll">Tasker RR. Central pain states. In: Principles and Practice of Pain Medicine, Bajwa ZH (Ed), McGraw-Hill, Warfield 2004. p.394.</li><li><a class="nounderline abstract_t">Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009; 32:1.</a></li><li><a class="nounderline abstract_t">Canavero S. Dynamic reverberation. A unified mechanism for central and phantom pain. Med Hypotheses 1994; 42:203.</a></li><li><a class="nounderline abstract_t">Rowbotham MC. Mechanisms of neuropathic pain and their implications for the design of clinical trials. Neurology 2005; 65:S66.</a></li><li><a class="nounderline abstract_t">Rodrigues P, da Silva B, Trevisan G. A systematic review and meta-analysis of neuropathic pain in multiple sclerosis: Prevalence, clinical types, sex dimorphism, and increased depression and anxiety symptoms. Neurosci Biobehav Rev 2023; 154:105401.</a></li><li><a class="nounderline abstract_t">Seixas D, Foley P, Palace J, et al. Pain in multiple sclerosis: a systematic review of neuroimaging studies. Neuroimage Clin 2014; 5:322.</a></li><li><a class="nounderline abstract_t">Heitmann H, Biberacher V, Tiemann L, et al. Prevalence of neuropathic pain in early multiple sclerosis. Mult Scler 2016; 22:1224.</a></li><li><a class="nounderline abstract_t">O'Donnell MJ, Diener HC, Sacco RL, et al. Chronic pain syndromes after ischemic stroke: PRoFESS trial. Stroke 2013; 44:1238.</a></li><li><a class="nounderline abstract_t">Manzoni GC, Torelli P. Epidemiology of typical and atypical craniofacial neuralgias. Neurol Sci 2005; 26 Suppl 2:s65.</a></li><li><a class="nounderline abstract_t">Andersen G, Vestergaard K, Ingeman-Nielsen M, Jensen TS. Incidence of central post-stroke pain. Pain 1995; 61:187.</a></li><li><a class="nounderline abstract_t">Harno H, Haapaniemi E, Putaala J, et al. Central poststroke pain in young ischemic stroke survivors in the Helsinki Young Stroke Registry. Neurology 2014; 83:1147.</a></li><li><a class="nounderline abstract_t">Frese A, Husstedt IW, Ringelstein EB, Evers S. Pharmacologic treatment of central post-stroke pain. Clin J Pain 2006; 22:252.</a></li><li><a class="nounderline abstract_t">Nicholson BD. Evaluation and treatment of central pain syndromes. Neurology 2004; 62:S30.</a></li><li><a class="nounderline abstract_t">Boivie J, Leijon G, Johansson I. Central post-stroke pain--a study of the mechanisms through analyses of the sensory abnormalities. Pain 1989; 37:173.</a></li><li><a class="nounderline abstract_t">Widar M, Samuelsson L, Karlsson-Tivenius S, Ahlström G. Long-term pain conditions after a stroke. J Rehabil Med 2002; 34:165.</a></li><li class="breakAll">Tasker RR, Watson CPN. The treatment of central pain. In: Neurological Therapeutics: Principles and Practice, Noseworthy JH (Ed), Martin Dunitz, London 2003. p.214.</li><li><a class="nounderline abstract_t">Iizuka O, Hosokai Y, Mori E. Trigeminal neuralgia due to pontine infarction. Neurology 2006; 66:48.</a></li><li><a class="nounderline abstract_t">Kim JB, Yu S. Neurological picture. Trigeminal neuralgia after pontine infarction affecting the ipsilateral trigeminal nerve. J Neurol Neurosurg Psychiatry 2013; 84:881.</a></li><li><a class="nounderline abstract_t">MacGowan DJ, Janal MN, Clark WC, et al. Central poststroke pain and Wallenberg's lateral medullary infarction: frequency, character, and determinants in 63 patients. Neurology 1997; 49:120.</a></li><li><a class="nounderline abstract_t">Bogousslavsky J, Regli F, Uske A. Thalamic infarcts: clinical syndromes, etiology, and prognosis. Neurology 1988; 38:837.</a></li><li><a class="nounderline abstract_t">Bowsher D. Central pain: clinical and physiological characteristics. J Neurol Neurosurg Psychiatry 1996; 61:62.</a></li><li><a class="nounderline abstract_t">Liampas A, Velidakis N, Georgiou T, et al. Prevalence and Management Challenges in Central Post-Stroke Neuropathic Pain: A Systematic Review and Meta-analysis. Adv Ther 2020; 37:3278.</a></li><li><a class="nounderline abstract_t">Vukojevic Z, Dominovic Kovacevic A, Peric S, et al. Frequency and features of the central poststroke pain. J Neurol Sci 2018; 391:100.</a></li><li><a class="nounderline abstract_t">Nowacki A, Zhang D, Wermelinger J, et al. Directional recordings of somatosensory evoked potentials from the sensory thalamus in chronic poststroke pain patients. Clin Neurophysiol 2023; 151:50.</a></li><li><a class="nounderline abstract_t">Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118:289.</a></li><li><a class="nounderline abstract_t">Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17:1113.</a></li><li><a class="nounderline abstract_t">Dowell D, Ragan KR, Jones CM, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022; 71:1.</a></li><li><a class="nounderline abstract_t">Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag 2014; 19:328.</a></li><li><a class="nounderline abstract_t">Leijon G, Boivie J. Central post-stroke pain--a controlled trial of amitriptyline and carbamazepine. Pain 1989; 36:27.</a></li><li><a class="nounderline abstract_t">Chen KY, Li RY. Efficacy and safety of different antidepressants and anticonvulsants in central poststroke pain: A network meta-analysis and systematic review. PLoS One 2022; 17:e0276012.</a></li><li><a class="nounderline abstract_t">Mulla SM, Wang L, Khokhar R, et al. Management of Central Poststroke Pain: Systematic Review of Randomized Controlled Trials. Stroke 2015; 46:2853.</a></li><li><a class="nounderline abstract_t">Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25:81.</a></li><li><a class="nounderline abstract_t">Kalita J, Chandra S, Misra UK. Pregabalin and lamotrigine in central poststroke pain: A pilot study. Neurol India 2017; 65:506.</a></li><li><a class="nounderline abstract_t">Crayton H, Heyman RA, Rossman HS. A multimodal approach to managing the symptoms of multiple sclerosis. Neurology 2004; 63:S12.</a></li><li class="breakAll">Information on carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics) with FDA Alerts. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107834.htm (Accessed on January 05, 2011).</li><li><a class="nounderline abstract_t">Vestergaard K, Andersen G, Gottrup H, et al. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 2001; 56:184.</a></li><li><a class="nounderline abstract_t">Mahesh B, Singh VK, Pathak A, et al. Efficacy of Duloxetine in Patients with Central Post-stroke Pain: A Randomized Double Blind Placebo Controlled Trial. Pain Med 2023; 24:610.</a></li><li><a class="nounderline abstract_t">Kim NY, Lee SC, Kim YW. Effect of Duloxetine for the Treatment of Chronic Central Poststroke Pain. Clin Neuropharmacol 2019; 42:73.</a></li><li><a class="nounderline abstract_t">Kumar B, Kalita J, Kumar G, Misra UK. Central poststroke pain: a review of pathophysiology and treatment. Anesth Analg 2009; 108:1645.</a></li><li><a class="nounderline abstract_t">Guay DR. Adjunctive agents in the management of chronic pain. Pharmacotherapy 2001; 21:1070.</a></li><li><a class="nounderline abstract_t">Solaro C, Messmer Uccelli M. Pharmacological management of pain in patients with multiple sclerosis. Drugs 2010; 70:1245.</a></li><li><a class="nounderline abstract_t">Franklin GM, American Academy of Neurology. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology 2014; 83:1277.</a></li><li><a class="nounderline abstract_t">Flaster M, Meresh E, Rao M, Biller J. Central poststroke pain: current diagnosis and treatment. Top Stroke Rehabil 2013; 20:116.</a></li><li><a class="nounderline abstract_t">Antal A. Transcranial Direct Current Stimulation in the Treatment of Facial Pain. Prog Neurol Surg 2020; 35:116.</a></li><li><a class="nounderline abstract_t">Cruccu G, Garcia-Larrea L, Hansson P, et al. EAN guidelines on central neurostimulation therapy in chronic pain conditions. Eur J Neurol 2016; 23:1489.</a></li><li><a class="nounderline abstract_t">Brown JA, Pilitsis JG. Motor cortex stimulation for central and neuropathic facial pain: a prospective study of 10 patients and observations of enhanced sensory and motor function during stimulation. Neurosurgery 2005; 56:290.</a></li><li><a class="nounderline abstract_t">Tanei T, Kajita Y, Takebayashi S, et al. Predictive Factors Associated with Pain Relief of Spinal Cord Stimulation for Central Post-stroke Pain. Neurol Med Chir (Tokyo) 2019; 59:213.</a></li><li><a class="nounderline abstract_t">Xu W, Zhang C, Sun B, Li D. Sustainable Effects of 8-Year Intermittent Spinal Cord Stimulation in a Patient with Thalamic Post-Stroke Pain. World Neurosurg 2020; 143:223.</a></li><li><a class="nounderline abstract_t">Tomycz ND, Deibert CP, Moossy JJ. Cervicomedullary junction spinal cord stimulation for head and facial pain. Headache 2011; 51:418.</a></li><li><a class="nounderline abstract_t">Radiansyah RS, Hadi DW. Repetitive transcranial magnetic stimulation in central post-stroke pain: current status and future perspective. Korean J Pain 2023; 36:408.</a></li><li><a class="nounderline abstract_t">Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clin Neurophysiol 2020; 131:474.</a></li><li><a class="nounderline abstract_t">Sachs AJ, Babu H, Su YF, et al. Lack of efficacy of motor cortex stimulation for the treatment of neuropathic pain in 14 patients. Neuromodulation 2014; 17:303.</a></li><li><a class="nounderline abstract_t">Franzini A, Ninatti G, Rossini Z, et al. Gamma Knife Central Lateral Thalamotomy for Chronic Neuropathic Pain: A Single-Center, Retrospective Study. Neurosurgery 2023; 92:363.</a></li><li><a class="nounderline abstract_t">Gallay MN, Magara AE, Moser D, et al. Magnetic resonance-guided focused ultrasound central lateral thalamotomy against chronic and therapy-resistant neuropathic pain: retrospective long-term follow-up analysis of 63 interventions. J Neurosurg 2023; 139:615.</a></li><li><a class="nounderline abstract_t">Ben-Haim S, Mirzadeh Z, Rosenberg WS. Deep brain stimulation for intractable neuropathic facial pain. Neurosurg Focus 2018; 45:E15.</a></li><li class="breakAll">Dydyk AM, Munakomi S.. StatPearls, StatPearls Publishing, Treasure Island (FL) 2023.</li><li><a class="nounderline abstract_t">Hosomi K, Seymour B, Saitoh Y. Modulating the pain network--neurostimulation for central poststroke pain. Nat Rev Neurol 2015; 11:290.</a></li></ol></div><div id="topicVersionRevision">Topic 3324 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22719000" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Assessing the risk of central post-stroke pain of thalamic origin by lesion mapping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18848810" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A study of clinical, magnetic resonance imaging, and somatosensory-evoked potential in central post-stroke pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18848810" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A study of clinical, magnetic resonance imaging, and somatosensory-evoked potential in central post-stroke pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19679277" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Central post-stroke pain: clinical characteristics, pathophysiology, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24500412" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neuropathic pain: mechanisms and their clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24500412" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Neuropathic pain: mechanisms and their clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19400724" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Neuropathic pain: a maladaptive response of the nervous system to damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8057978" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Dynamic reverberation. A unified mechanism for central and phantom pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16385106" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mechanisms of neuropathic pain and their implications for the design of clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37777076" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A systematic review and meta-analysis of neuropathic pain in multiple sclerosis: Prevalence, clinical types, sex dimorphism, and increased depression and anxiety symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25161898" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pain in multiple sclerosis: a systematic review of neuroimaging studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26480924" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevalence of neuropathic pain in early multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23559265" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Chronic pain syndromes after ischemic stroke: PRoFESS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15926023" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Epidemiology of typical and atypical craniofacial neuralgias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7659428" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Incidence of central post-stroke pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25128182" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Central poststroke pain in young ischemic stroke survivors in the Helsinki Young Stroke Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16514325" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pharmacologic treatment of central post-stroke pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15007162" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evaluation and treatment of central pain syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2748190" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Central post-stroke pain--a study of the mechanisms through analyses of the sensory abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12201611" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-term pain conditions after a stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12201611" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term pain conditions after a stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16401844" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Trigeminal neuralgia due to pontine infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23532720" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neurological picture. Trigeminal neuralgia after pontine infarction affecting the ipsilateral trigeminal nerve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9222179" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Central poststroke pain and Wallenberg's lateral medullary infarction: frequency, character, and determinants in 63 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3368064" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Thalamic infarcts: clinical syndromes, etiology, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8676164" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Central pain: clinical and physiological characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32451951" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prevalence and Management Challenges in Central Post-Stroke Neuropathic Pain: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30103954" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Frequency and features of the central poststroke pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37156120" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Directional recordings of somatosensory evoked potentials from the sensory thalamus in chronic poststroke pain patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16213659" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Algorithm for neuropathic pain treatment: an evidence based proposal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20402746" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36327391" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25479151" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2465530" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Central post-stroke pain--a controlled trial of amitriptyline and carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36227855" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy and safety of different antidepressants and anticonvulsants in central poststroke pain: A network meta-analysis and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26359361" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Management of Central Poststroke Pain: Systematic Review of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637113" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28488610" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pregabalin and lamotrigine in central poststroke pain: A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15596731" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A multimodal approach to managing the symptoms of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15596731" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A multimodal approach to managing the symptoms of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11160953" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Lamotrigine for central poststroke pain: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36409018" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy of Duloxetine in Patients with Central Post-stroke Pain: A Randomized Double Blind Placebo Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31085946" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effect of Duloxetine for the Treatment of Chronic Central Poststroke Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19372350" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Central poststroke pain: a review of pathophysiology and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560197" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Adjunctive agents in the management of chronic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20568832" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pharmacological management of pain in patients with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25267983" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23611852" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Central poststroke pain: current diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32694260" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Transcranial Direct Current Stimulation in the Treatment of Facial Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27511815" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : EAN guidelines on central neurostimulation therapy in chronic pain conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15670377" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Motor cortex stimulation for central and neuropathic facial pain: a prospective study of 10 patients and observations of enhanced sensory and motor function during stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31061256" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Predictive Factors Associated with Pain Relief of Spinal Cord Stimulation for Central Post-stroke Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32750518" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Sustainable Effects of 8-Year Intermittent Spinal Cord Stimulation in a Patient with Thalamic Post-Stroke Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21269299" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cervicomedullary junction spinal cord stimulation for head and facial pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37752663" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Repetitive transcranial magnetic stimulation in central post-stroke pain: current status and future perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31901449" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24773411" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Lack of efficacy of motor cortex stimulation for the treatment of neuropathic pain in 14 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36637271" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Gamma Knife Central Lateral Thalamotomy for Chronic Neuropathic Pain: A Single-Center, Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36840733" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Magnetic resonance-guided focused ultrasound central lateral thalamotomy against chronic and therapy-resistant neuropathic pain: retrospective long-term follow-up analysis of 63 interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30064325" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Deep brain stimulation for intractable neuropathic facial pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30064325" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Deep brain stimulation for intractable neuropathic facial pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25896085" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Modulating the pain network--neurostimulation for central poststroke pain.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
